EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma—UK Tertiary Cancer Centre Experience

Kai Tai Derek Yeung iD, Simon Gomberg, William Hodgson, Petula Jefferies, David Cunningham iD, Sheela Rao, Ian Chau iD, Naureen Starling iD, Charlotte Fribbens, Avani Athauda iD, Diana Tait iD, Irene Chong und 6 weitere

Cancers · 14.05.2026 · 18 (10) · 1597

DOI: 10.3390/cancers18101597 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 14.05.2026. Verfasst von Kai Tai Derek Yeung und 17 weiteren Autor:innen. Beteiligte Einrichtung: Royal Marsden Hospital, London SW3 6JJ, UK. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer-related mortality. Radiological distinctions between borderline resectable (BR) and locally advanced disease (LA) are increasingly recognised as imperfect when considered without dynamic assessment. Neoadjuvant therapy (NAT) improves outcomes through tumour downstaging and early treatment of occult metastatic disease, but the optimal NAT strategy, particularly in BR disease, remains uncertain. Published data evaluating combined systemic anti-cancer therapies (SACT) with or without chemoradiation (CRT) are limited and heterogeneous.

Methods

This is a single-centre retrospective analysis of 44 patients with BR PDAC and a comparator cohort of 121 patients with LA PDAC treated with a total neoadjuvant approach of SACT with or without CRT and surgical resection between June 2017 and September 2022.

Results

Median overall survival (OS) did not differ significantly between BR and LA disease (18 vs. 16 months, p = 0.14). Following NAT, 47.7% of BR and 18.1% of LA patients were anatomically suitable for surgical resection. Among unresected BR and LA patients, those treated with CRT in addition to SACT had a median OS of 18 and 21 months respectively. In the resected subgroup, resection margin status was the primary factor associated with survival; with R0 resection conferring a substantial OS advantage over R1, irrespective of initial BR/LA classification as diagnosis (47 vs. 22 months, p < 0.001).

Conclusions

Despite anatomical differences at diagnosis, BR and LA PDAC demonstrated comparable survival outcomes when treated with total neoadjuvant strategies in this cohort. These findings challenge traditional radiological staging-based treatment paradigms and confirm that a margin-negative surgical resection offered the greatest opportunity for long-term survival for BR/LA PDAC patients.

Schlagwörter

Stichwörter der Autor:innen

chemoradiationneoadjuvant treatmentpancreatic adenocarcinoma

Autor:innen und Institutionen

  • Royal Marsden Hospital, London SW3 6JJ, UK.
  • The Institute of Cancer Research, London SW7 3RP, UK.
  • Surgery & Cancer, Imperial College London, London SW7 2AZ, UK.

ORCID-Profile: Kai Tai Derek Yeung, David Cunningham, Ian Chau, Naureen Starling, Avani Athauda, Diana Tait, Arabella Hunt, Magnus T Dillon, Sacheen Kumar, Katharine Aitken

Zitieren

APA

Yeung, K. T. D., Gomberg, S., Hodgson, W., Jefferies, P., Cunningham, D., Rao, S., Chau, I., Starling, N., Fribbens, C., Athauda, A., Tait, D., Chong, I., Hunt, A., Dillon, M. T., Kumar, S., Jiao, L. R., Bhogal, R. H., & Aitken, K. (2026). Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma—UK Tertiary Cancer Centre Experience. Cancers, 18(10), 1597. https://doi.org/10.3390/cancers18101597

Vancouver

Yeung KTD, Gomberg S, Hodgson W, Jefferies P, Cunningham D, Rao S, et al. Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma—UK Tertiary Cancer Centre Experience. Cancers. 2026;18(10):1597. doi:10.3390/cancers18101597

BibTeX
@article{Yeung2026,
  author = {Yeung, Kai Tai Derek and Gomberg, Simon and Hodgson, William and Jefferies, Petula and Cunningham, David and Rao, Sheela and Chau, Ian and Starling, Naureen and Fribbens, Charlotte and Athauda, Avani and Tait, Diana and Chong, Irene and Hunt, Arabella and Dillon, Magnus T and Kumar, Sacheen and Jiao, Long R and Bhogal, Ricky H and Aitken, Katharine},
  title = {Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma—UK Tertiary Cancer Centre Experience},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1597},
  doi = {10.3390/cancers18101597}
}
Kostenlos starten →